Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Patients coming off weight loss jabs need support and advice for at least a year to ensure lasting benefit from the drugs, the UK’s medicine watchdog has said. An estimated four in five patients who ...

Learn more about the gut microbiome’s digestion of the amino acid tryptophan, which creates byproducts with potential for ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions like obesity and type 2 diabetes, many lacked insurance or a routine place for ...

Nutritionists say it’s possible – and all without pricey prescription injections and weight loss supplements. Amira Arasteh reports ...

* Facebook posts //provide vital real-world data beyond clinical trials Ozempic , Wegovy, Rybelsus, and Mounjaro are glucagon ...

By Vijay Kumar Malesu A diabetes drug may hold the key to slowing the aging process. New research finds semaglutide ...

The IND application of IBI3032 was accepted by China’s National Medical Products Administration (NMPA) and approved by the U.S. Food and Drug Administration (FDA). A multi-regional Phase 1 clinical ...